Compare YUMC & ICLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YUMC | ICLR |
|---|---|---|
| Founded | 1987 | 1990 |
| Country | China | Ireland |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8B | 13.1B |
| IPO Year | 2016 | 2001 |
| Metric | YUMC | ICLR |
|---|---|---|
| Price | $42.93 | $163.67 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 18 |
| Target Price | $61.92 | ★ $184.41 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 11-03-2026 | 10-27-2026 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | ★ 7.73 | N/A |
| EPS | ★ 1.57 | N/A |
| Revenue | ★ $11,797,000,000.00 | N/A |
| Revenue This Year | $9.17 | N/A |
| Revenue Next Year | $6.17 | $3.63 |
| P/E Ratio | $26.61 | ★ $12.91 |
| Revenue Growth | ★ 4.37 | N/A |
| 52 Week Low | $40.02 | $66.57 |
| 52 Week High | $58.39 | $203.91 |
| Indicator | YUMC | ICLR |
|---|---|---|
| Relative Strength Index (RSI) | 57.35 | 47.47 |
| Support Level | $42.45 | $162.32 |
| Resistance Level | $44.80 | $181.71 |
| Average True Range (ATR) | 0.53 | 7.04 |
| MACD | 0.34 | -0.65 |
| Stochastic Oscillator | 90.77 | 34.91 |
Yum China is the largest restaurant operator in China, with over 18,000 locations and USD 12 billion in systemwide sales as of 2025. It generates revenue primarily from its own restaurants and franchise fees. While KFC and Pizza Hut are its flagship brands, Yum China's portfolio also includes Little Sheep, Taco Bell, Huang Ji Huang, and Lavazza.As a trademark licensee of Yum Brands, Yum China pays 3% of KFC and Pizza Hut's systemwide sales to its former parent, from which it spun off in 2016. However, even before the separation, Yum China was granted substantial autonomy, giving its Chinese leadership decision-making authority over menu, supply chain, and marketing—an unusual practice for Western chains at the time.
Icon is a global contract research organization that provides outsourced clinical development services to pharmaceutical and biotechnology firms. Icon supports clients across late-stage clinical trials through the regulatory approval process and postmarket studies. Icon's services include clinical trial management, patient recruitment, data analytics, laboratory services, and regulatory consulting. With more than 40,000 employees operating in over 50 countries, the company partners with life sciences firms to run clinical trials and bring new drugs to market.